High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplant for Non-Hodgkin's Lymphoma

Phase 2

Completed

• Conditions: Lymphoma, Non-Hodgkin; Blood and Marrow Transplant (BMT); Lymphomas: Non-Hodgkin

• Registration Number: NCT00186394
• Lead Sponsor: Stanford University

Brief Summary

To evaluate the role of allogeneic hematopoietic cell transplantation in the treatment of NHL.

Detailed Description

To determine safety and toxicity of a regimen of high dose chemotherapy with allogeneic peripheral blood progenitor cell transplantation; determine the efficacy of the procedure by following clinical outcomes and quality of life measures; and evaluate graft versus host disease incidence and severity with regimen.

Study Timeline

• Study Start: 2000-04
• Study First Submitted: 2005-09-13
• Study First Submitted QC: 2005-09-13
• Study First Posted: 2005-09-16
• Primary Completion: 2006-12
• Study Completion: 2006-12
• Status Verified: 2010-07
• Last Update Submitted: 2010-07-23
• Last Update Posted: 2010-07-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 35

Inclusion Criteria

Morphologically confirmed relapsed non-Hodgkin's lymphoma

Age: >18 and <61 years of age

Signed informed consent

Exclusion Criteria

Hepatic dysfunction defined by serum transaminases >2.5X normal values

Serum creatinine of > 2 mg/dl or creatinine clearance < 60 ml/min

Diseases other than non-Hodgkin's lymphoma

Prior bone marrow transplant procedure

Severe psychological or medical illness

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Safety
Toxicity
Efficacy

Secondary Outcome Measures

Name	Time	Method
Incidence of acute and chronic GVHD

Trial Locations

Locations (1)

Stanford University School of Medicine; 🇺🇸 Stanford, California, United States